Tech Company Financing Transactions

Arrakis Therapeutics Funding Round

Arrakis Therapeutics, based in Waltham, raised $38 million in funding from Canaan Partners, Advent Life Sciences and Celgene.

Transaction Overview

Company Name
Arrakis Therapeutics
Announced On
2/28/2017
Transaction Type
Venture Equity
Amount
$38,000,000
Round
Series A
Investors

Canaan Partners (Lead Investor) (Colleen Cuffaro)

Advent Life Sciences (Raj Parekh)

Celgene (Russell Petter)

private investors (Henri Termeer)

Osage Partners (Matthew Cohen)

Proceeds Purpose
The proceeds from the Series A financing will be used to advance Arrakis' proprietary discovery platforms, comprised of a high-throughput, comprehensive system of bioinformatics tools, assays and chemical libraries that can identify new ribonucleic acid (RNA) targets and create new small-molecule drugs.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
830 Winter St.
Waltham, MA 02451
USA
Phone
Undisclosed
Website
www.arrakistx.com
Email Address
[email protected]
Overview
The therapeutic potential of the human transcriptome, the set of all RNAs transcribed from DNA, remains largely unexplored. By harnessing new insights into RNA structure and dynamics, Arrakis is opening the transcriptome to therapy by small-molecule medicines to treat patients not cured by today's medicines.
Profile
Arrakis Therapeutics LinkedIn Company Profile
Social Media
Arrakis Therapeutics Company Twitter Account
Company News
Arrakis Therapeutics News
Facebook
Arrakis Therapeutics on Facebook
YouTube
Arrakis Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Michael Gilman
  Michael Gilman LinkedIn Profile  Michael Gilman Twitter Account  Michael Gilman News  Michael Gilman on Facebook
Chief Scientific Officer
Russell Petter
  Russell Petter LinkedIn Profile  Russell Petter Twitter Account  Russell Petter News  Russell Petter on Facebook
Vice President
James Barsoum
  James Barsoum LinkedIn Profile  James Barsoum Twitter Account  James Barsoum News  James Barsoum on Facebook
Vice President
Gnanasambandam Kumaravel
  Gnanasambandam Kumaravel LinkedIn Profile  Gnanasambandam Kumaravel Twitter Account  Gnanasambandam Kumaravel News  Gnanasambandam Kumaravel on Facebook
VP - Bus. Development
Daniel Koerwer
  Daniel Koerwer LinkedIn Profile  Daniel Koerwer Twitter Account  Daniel Koerwer News  Daniel Koerwer on Facebook
VP - Operations
Heather Lounsbury
  Heather Lounsbury LinkedIn Profile  Heather Lounsbury Twitter Account  Heather Lounsbury News  Heather Lounsbury on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/28/2017: Voicera venture capital transaction
Next: 2/28/2017: RoosterBio venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to report on tech company VC transactions. VC investment data records on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.